不过美国在立法方面行动一直很慢,尤其是联邦层级的立法。“阳光法案”是作为巴拉克??奥巴马医疗改革项目的一部分通过的,它是第一部为提高透明度的国家级法案。每年,医药和器械公司必须公开支付信息,以及其他用在医生身上的开销。他们也必须汇报研究经费、医生在医疗公司投资股权。第一批申报文案将于2017年9月30日前上传至公共数据库中。
The rule’s broader effects are uncertain. It does not limit firms’ interactions with doctors; it merely requires them to be reported. Certain marketing techniques, such as providing free drug samples, are exempt. And in some ways the law is already out of date. It regulates only doctors and some hospitals, not nurses, pharmacists or hospital bureaucrats who have a growing role in patients’ treatment.
这项规定会产生怎样更大范围的影响还不得而知。它并没有限制企业与医生之间的往来;仅仅只是要求他们上报相关信息。某些营销方案不在监管之列,比如为医生提供免费的药物样品。法律在某些方面已经过时了,它所监管的只有医生和某些医院,却不包括护士、药剂师或者医院的行政人员,而这些人在病人的治疗中发挥的作用越来越大。
Nevertheless, the Sunshine law is likely to lead to at least one change. Firms already have data on each doctor’s prescriptions, points out Chris Wright of ZS Associates, a consultancy. The Sunshine law will also provide them with exhaustive data on how much they and their competitors spend to market drugs to that doctor. This will let firms track which type of marketing spurs the most prescriptions. Companies will not stop wooing doctors. They may simply get better at it.
【揭露药医利益关系的新招】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15